文献速递慢性肾脏病肾小球疾病

补体激活生物标志物在显性糖尿病肾病中的临床价值

Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy.
PubMed 文献 · Kidney Int Rep · 2019-03-20

研究前瞻性随访83例显性糖尿病肾病患者,重复检测尿sC5b-9等补体片段及炎症纤维化标志物,并与63例自身免疫性肾小球肾炎比较。发现尿MAC水平与GFR下降、蛋白尿及炎症纤维化相关,且蛋白尿与sC5b-9存在交互作用(P=0.03)。提示补体激活在糖尿病肾病中具有临床相关性。

要点

  • 尿sC5b-9水平与糖尿病肾病患者GFR下降速率、蛋白尿及炎症纤维化标志物相关。
  • 蛋白尿与尿sC5b-9存在显著交互作用(P=0.03),高MAC者蛋白尿与肾功能下降关系更明显。
  • 按蛋白尿分层后,糖尿病肾病患者尿sC5b-9水平与自身免疫性肾小球肾炎相当。

核心结论

  • 显性糖尿病肾病患者尿中可检测到MAC,水平与自身免疫性肾小球肾炎相当。
  • 尿MAC与GFR下降相关,支持补体激活及其检测在糖尿病肾病中具有临床相关性。

研究设计与样本

  • 前瞻性随访83例显性糖尿病肾病患者,重复测量蛋白尿、补体片段、MCP-1和TGF-β1。
  • 采用一般线性模型和重复测量分析评估独立性与交互作用。
  • 与63例活动性局灶节段性肾小球硬化、ANCA相关性血管炎、膜性和IgA肾病患者比较补体水平。

主要发现

  • 糖尿病队列初始GFR为25 ± 9 ml/min per 1.73 m2,肾功能下降速率为2.9 ± 3.0 ml/min per 1.73 m2 per year。
  • 所有补体生物标志物彼此强相关,并与炎症纤维化标志物、蛋白尿及肾功能下降速率相关。
  • 蛋白尿水平与尿sC5b-9存在显著交互作用(P = 0.03):高尿MAC个体中蛋白尿与肾功能下降速率的关系比低尿MAC个体更明显。
  • 按蛋白尿水平分层后,糖尿病肾病患者尿sC5b-9水平与自身免疫性肾小球肾炎相当。

关键数值与推荐

  • 糖尿病队列初始GFR为25 ± 9 ml/min per 1.73 m2。
  • 肾功能下降速率为2.9 ± 3.0 ml/min per 1.73 m2 per year。
  • 蛋白尿与尿sC5b-9交互作用P = 0.03。

临床怎么用

  • 在显性糖尿病肾病患者中可考虑检测尿sC5b-9以评估补体激活状态。
  • 高尿MAC且蛋白尿明显的患者肾功能下降风险可能更高,需加强监测。
  • 补体激活标志物可能有助于识别糖尿病肾病中炎症纤维化活跃的亚群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Experimental studies support a role of complement activation in diabetic nephropathy (DN), yet few clinical correlates exist. We evaluated urinary levels of sC5b-9 membrane attack complex (MAC) in patients with overt DN, and examined its association with the glomerular filtration rate (GFR) decline, proteinuria, and inflammatory biomarkers. We explored different complement pathways and compared our findings to autoimmune glomerulonephritis. METHODS: We prospectively followed 83 patients with DN and obtained repeated measurements of proteinuria, complement fragments (sC5b-9, C4a, C1q, mannose-binding lectin-associated serine protease [MASP]-1, and factor Bb), monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor (TGF)-β1. We assessed independence and interactions using general linear models and repeated measures analyses and compared levels with subjects with active focal and segmental glomerulosclerosis, ANCA-associated vasculitis, and membranous and IgA nephropathies (n = 63). RESULTS: The diabetic cohort had an initial GFR of 25 ± 9 ml/min per 1.73 m2 and a renal function decline of 2.9 ± 3.0 ml/min per 1.73 m2 per year. All complement biomarkers were strongly intercorrelated and associated with biomarker inflammation and fibrosis, proteinuria, and the rate of renal function decline. There was a significant interaction (P = 0.03) between the level of proteinuria and urinary sC5b-9: in individuals with higher levels of urinary MAC, the relationship between proteinuria and the rate of renal function decline was more pronounced than in those with low urinary MAC. Finally, patients with DN had levels of urinary sC5b-9 comparable to autoimmune glomerulonephritis, when stratified by the level of proteinuria. CONCLUSION: Urinary MAC is present in patients with overt DN at levels comparable to autoimmune glomerulonephritis and correlates with the GFR decline, supporting that complement activation and its measurement are clinically relevant in DN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Pelletier K, Bonnefoy A, Chapdelaine H, et al. Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy. Kidney Int Rep. 2019. PMID: 31194090. doi:10.1016/j.ekir.2019.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。